about
Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-AnalysisMedical management of brain tumors and the sequelae of treatment.TCTP contains a BH3-like domain, which instead of inhibiting, activates Bcl-xLThe therapeutic management of bleeding and thrombotic disorders complicating CNS malignancies.Venous thromboembolism (VTE) and glioblastoma.CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas.Decision-making in a patient with cardiac arrest due to venous thromboembolism within 24 h after glioblastoma resection.Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations.Risk factors associated with peripherally inserted central venous catheter-related large vein thrombosis in neurological intensive care patients.Combination therapy for scalp angiosarcoma using bevacizumab and chemotherapy: a case report and review of literature.Venous thromboembolism in high grade glioma among surgical patients: results from a single center over a 10 year period.Bevacizumab in high-grade gliomas: past, present, and future.Managing Disease and Therapy-Related Complications in Patients with Central Nervous System Tumors.Predictors of Venous Thromboembolism in Patients with Glioblastoma.Venous thromboembolism prophylaxis in brain tumor patients undergoing craniotomy: a meta-analysis.Metabolic, electrolytes disorders and tromboembolic risk in malignant glioma patients.Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients.Hypoxic cell waves around necrotic cores in glioblastoma: a biomathematical model and its therapeutic implications.Remote Cerebellar Hemorrhage after Removal of a Supratentorial Glioma without Perioperative CSF Loss: A Case Report.Thromboembolic disease in patients with high-grade glioma.A pilot study on the applicability of thromboelastometry in detecting brain tumour-induced hypercoagulation.Therapeutic Anticoagulation in Patients with Primary Brain Tumors or Secondary Brain Metastasis.A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network.Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas.Hypoxia in Gliomas: Opening Therapeutical Opportunities Using a Mathematical-Based Approach.Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients.Venous Thromboembolism in Brain Tumor Patients.Circulating procoagulant microparticles in cancer patients.Increased expression of von Willebrand factor gene is associated with poorer survival in primary lower grade glioma
P2860
Q26783779-45FBEC2A-62DB-4289-93EE-29A891DE4A42Q26992174-D9C9A692-3054-44DA-A856-54DA9608B22DQ28272524-96067399-12EF-447D-A1FC-8ADD9582BBD4Q33402515-FD97A4EA-B8EF-4481-8CB8-D65CD12AD3A8Q33422929-19CAA11C-F451-44D8-BE1D-F449F2F8D541Q34437996-898E355B-EAD9-444D-817D-19D408311D99Q34511705-0D20093D-27AC-441A-B8DD-2E474659832CQ36163379-E966EB9D-C82E-44CE-A82C-E43E6C696E9EQ36787777-E80F03C7-97C1-46A8-9644-04F0A09B003DQ37628002-654BE86C-9FD9-4CB1-B266-90C93560C795Q37960412-3A910AE2-3EE8-4873-9395-C0C4BDBC56A7Q38119223-264F0478-3D24-4979-9617-F55602454449Q38233992-52550A80-B9DA-4A3E-A6E4-91499EE553FFQ38386873-2C881B7C-5911-4217-9CEF-637CC3E5B20CQ38542829-EFDFE7CF-999C-458A-AF45-F2D35D68B957Q38627862-A9D1B6B4-FEA0-4194-B61A-25B701405018Q38945606-D7A2B49E-2236-4D63-A716-560CD0EE6951Q39257753-45C5EBDA-7F78-457F-989F-86BF60218BF2Q39626842-A95D2370-5946-43B7-A646-266F01C9D30BQ41883885-6B4FF8D7-F974-46E3-A45A-3571FA3FBD82Q42126676-E0036ED2-4D3A-43A6-9364-481D5F3A3BFCQ42407190-617C80B7-B16E-495D-AD68-9AB5B1478CFFQ47313341-2BC3230E-6E9B-4110-A458-B4A7A3185CE0Q47959893-D36B7624-5CA9-449F-935D-BD6C5A3BFDCCQ48318254-7BC02DBC-EF55-46E4-AC0D-0193F509BA57Q48444978-94B094A9-5964-41B6-8C8C-088152382E5BQ48479445-93473817-BE6E-4C68-B04B-33108F06DFD4Q49123780-F691EAEB-46E8-4B5D-8169-3D8DA80695EFQ51164297-152E9D5B-ED4D-467D-9F78-C63B57BA76EDQ53292843-4643FF18-E307-435E-9905-38B6759483E8Q57141790-599E3CC2-87E0-47F2-B250-11834A7393FD
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Venous thromboembolism in malignant gliomas
@ast
Venous thromboembolism in malignant gliomas
@en
type
label
Venous thromboembolism in malignant gliomas
@ast
Venous thromboembolism in malignant gliomas
@en
prefLabel
Venous thromboembolism in malignant gliomas
@ast
Venous thromboembolism in malignant gliomas
@en
P2093
P2860
P1476
Venous thromboembolism in malignant gliomas
@en
P2093
P2860
P304
P356
10.1111/J.1538-7836.2009.03690.X
P577
2009-11-13T00:00:00Z